Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

In reply: We thank Zagarella and colleagues for their comments and the opportunity to correct some misconceptions about the Multicenter Selective Lymphadenectomy Trial-1 study.1

It is unclear why they have taken exception to the reporting of disease-specific survival as this is a more robust end point than overall survival and, in this patient cohort (median age, 52 years), the two outcomes are likely equivalent.

The subgroup analysis of patients with lymph node involvement was preplanned, and the novel and robust statistical method (latent subgroup analysis) showed improved outcomes with early intervention for node-positive patients. This finding is intuitive, and Zagarella and colleagues provide no evidence as to why they consider this “unreliable”.

Sentinel lymph node biopsy (SLNB) has repeatedly been shown to be the most significant independent predictor of survival in clinically lymph node-negative patients, including by Mitra et al,2 also cited by Zagarella and colleagues. The use of ultrasound or other clinicopathological algorithms have not been reproducible and cannot be used a surrogate.3

Until a better test is developed, SLNB remains the gold standard staging test for clinically lymph node-negative patients with intermediate thickness melanoma.